Recently the ADA and the AHA came together to adjust the guidelines in diabetes patients with cardiovascular problems. They have agreed that managing the cardiovascular problems should be the guiding light in overall patient care, and worrying about A1c levels is of less importance. This is especially true in older patients.
These guidelines are related to medication selection, and now more than ever the SGLT-2 inhibitors appear to be the best choice to address both issues. Be sure to check out this month’s features, and if you want to know even more about how these compounds address cardiovascular problems, then check out the Homerun Slides that our publisher Steve Freed featured in Tuesday’s clinical newsletter.